News Novartis bullish about future despite Gleevec pain The patent loss of its biggest earning drug has hit Novartis’ revenues, which fell 1% in the third quarter, while operating income declining 3 per cent.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face